Treatment of Acute Lymphoblastic Leukemia in Children

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to reduce the side-effects from anti-leukemia therapy. The therapy in this study is based upon treatment information learned from prior clinical research programs as well as from laboratory research.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: Boston Children's Hospital; Boston Children’s Hospital; Columbia University; Laval University; Maine Children's Cancer Program; McMaster University; Ochsner Health System; San Jorge Children's Hospital (Puerto Rico); St. Justine's Hospital; Tulane University School of Medicine; University of Rochester
• Treatments: Asparaginase; BB 1101; Cortisol succinate; Cytarabine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Dexrazoxane; Doxorubicin; Hydrocortisone; Hydrocortisone 17-butyrate 21-propionate; Hydrocortisone acetate; Leucovorin; Liposomal doxorubicin; Methotrexate; Prednisone; Vincristine

Criteria

Inclusion Criteria:

• Acute lymphoblastic leukemia excluding known mature B-cell ALL by the presence of any of the following: surface immunoglobulin, L3 morphology, t(8;14) (q24;q32), t(8;22) or t(2;8)

• Age > 12 months but less than 18 years

Exclusion Criteria:

• Prior therapy except, 1 week of steroids, or emergent radiation therapy to the mediastinum

• Known HIV positive